Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB8018 in Crohn's Disease
NCT03709628Phase 1Completed
- Sponsor
- Enterome
- Start
- Mar 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of sibofimloc in Crohn's disease, sponsored by Enterome. Primary endpoints: Maximum Plasma Concentration at Day 13, Time to Maximum Plasma Concentration at Day 1 and 2 more. Started Mar 2018; status: completed.
02
Drugs
sibofimloc
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03709628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03709628.